PacBio (Nasdaq: PACB) today announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ. The deal will increase PacBio’s HiFi sequencing platforms across Azenta’s newly combined company and support Azenta’s mission to enable life science companies to deliver impactful breakthroughs and therapies to market faster.

PacBio’s HiFi sequencing technology uniquely combines the benefits of high accuracy with long read lengths, providing a comprehensive view of genomes and transcriptomes to scientists tackling complex genetic challenges. Azenta’s expanded investment in HiFi sequencing signifies the technology’s ability to unlock invaluable insights for researchers in academia, pharma, and biotech.

"Azenta is a global leader in genomics services, and we’re very pleased that our highly accurate HiFi sequencing technology will continue to underpin leading-edge research to build a healthier world for people everywhere," said Christian Henry, CEO at PacBio. "With a focus on the future, we are continuing to redefine what is possible in genomics."

With more than 20 years of experience specializing in DNA and RNA sequencing and synthesis services, working with over 6,000 institutions worldwide, Azenta is using PacBio Sequel IIe technology to offer enterprise-wide sample exploration and management solutions across the drug development pipeline.

"We are excited to significantly increase our capacity by offering a best-in-class long-read sequencing platform supporting customers through our unique solutions spanning broad genomics applications," said Ginger Zhou, vice president and general manager at Azenta Life Sciences. "The new Sequel IIe platform, in combination with our team of scientific experts, will enable our diverse customer base to obtain actionable data faster."